Cargando…

Repeatability of parametric methods for [(18)F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study

Accumulation of amyloid beta (Aβ) is one of the pathological hallmarks of Alzheimer’s disease (AD), which can be visualized using [(18)F]florbetapir positron emission tomography (PET). The aim of this study was to evaluate various parametric methods and to assess their test-retest (TRT) reliability....

Descripción completa

Detalles Bibliográficos
Autores principales:	Verfaillie, Sander CJ, Golla, Sandeep SV, Timmers, Tessa, Tuncel, Hayel, van der Weijden, Chris WJ, Schober, Patrick, Schuit, Robert C, van der Flier, Wiesje M, Windhorst, Albert D, Lammertsma, Adriaan A, van Berckel, Bart NM, Boellaard, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907981/ https://www.ncbi.nlm.nih.gov/pubmed/32321347 http://dx.doi.org/10.1177/0271678X20915403

Ejemplares similares

Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Test–retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
por: Timmers, Tessa, et al.
Publicado: (2019)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Classification of negative and positive (18)F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network
por: de Vries, Bart Marius, et al.
Publicado: (2020)

Precision estimates of relative and absolute cerebral blood flow in Alzheimer’s disease and cognitively normal individuals
por: Heeman, Fiona, et al.
Publicado: (2022)

Kinetics and 28-day test–retest repeatability and reproducibility of [(11)C]UCB-J PET brain imaging
por: Tuncel, Hayel, et al.
Publicado: (2020)

Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer’s disease
por: Visser, Denise, et al.
Publicado: (2022)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies
por: Tuncel, Hayel, et al.
Publicado: (2021)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Validation and test–retest repeatability performance of parametric methods for [(11)C]UCB-J PET
por: Tuncel, Hayel, et al.
Publicado: (2022)

Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
por: Visser, Denise, et al.
Publicado: (2020)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

Longitudinal Tau PET Using (18)F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
por: Visser, Denise, et al.
Publicado: (2023)

Test-retest variability of quantitative [(11)C]PIB studies in Alzheimer’s disease
por: Tolboom, Nelleke, et al.
Publicado: (2009)

Quantification of the novel N-methyl-d-aspartate receptor ligand [(11)C]GMOM in man
por: van der Doef, Thalia F, et al.
Publicado: (2015)

A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus
por: Wolters, Emma E., et al.
Publicado: (2018)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Reproducibility of quantitative (R)-[(11)C]verapamil studies
por: van Assema, Daniëlle ME, et al.
Publicado: (2012)

Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study
por: Wolters, E.E., et al.
Publicado: (2020)

Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study
por: Visser, Denise, et al.
Publicado: (2023)

First in human evaluation of [(18)F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors
por: van der Aart, Jasper, et al.
Publicado: (2018)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

In vivo tau pathology is associated with synaptic loss and altered synaptic function
por: Coomans, Emma M., et al.
Publicado: (2021)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Model selection criteria for dynamic brain PET studies
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

Grey zone amyloid burden affects memory function: the SCIENCe project
por: Ebenau, J. L., et al.
Publicado: (2020)

Longitudinal change in ATN biomarkers in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project
por: Verfaillie, Sander C. J., et al.
Publicado: (2019)

Tau protein spreads through functionally connected neurons in Alzheimer’s disease: a combined MEG/PET study
por: Schoonhoven, Deborah N, et al.
Publicado: (2023)

Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
por: Coomans, Emma M., et al.
Publicado: (2023)

P-Glycoprotein Function at the Blood–Brain Barrier: Effects of Age and Gender
por: van Assema, Daniëlle M. E., et al.
Publicado: (2012)

Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

Impact of New Scatter Correction Strategies on High-Resolution Research Tomograph Brain PET Studies
por: Mansor, Syahir, et al.
Publicado: (2016)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_650o5csqdf50ceft3ncdc027ge